Hikma Changes Registered Office
London, 3 May 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LEI:549300BNS685UXH4JI75)(LSE: HIK) (DIFX: HIK) today announces that its registered office has changed from 13 Hanover Square, London W1S 1HW to 1 New Burlington Place, London W1S 2HR with immediate effect. The move to 1 New Burlington Place creates the capacity Hikma requires to deliver its strategic plans.
-- ENDS --
Enquiries:
|
Hikma Pharmaceuticals PLC Peter Speirs, Company Secretary +44 (0)20 7399 2772 |
Notes to Editors:
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.
This information is provided by RNS